Sanford C. Bernstein downgraded shares of Haleon (NYSE:HLN – Free Report) from an outperform rating to a market perform rating in a research report report published on Wednesday morning, MarketBeat.com reports.
Several other analysts also recently commented on HLN. Morgan Stanley boosted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.95.
Check Out Our Latest Research Report on Haleon
Haleon Trading Down 4.0 %
Institutional Trading of Haleon
A number of institutional investors and hedge funds have recently modified their holdings of HLN. Fortitude Family Office LLC bought a new position in Haleon in the 3rd quarter worth $28,000. Versant Capital Management Inc increased its stake in shares of Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the period. Toronto Dominion Bank lifted its position in shares of Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Prospera Private Wealth LLC bought a new stake in Haleon during the 3rd quarter valued at approximately $57,000. Finally, BOKF NA grew its holdings in Haleon by 68.8% in the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after buying an additional 2,842 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Further Reading
- Five stocks we like better than Haleon
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What Are Trending Stocks? Trending Stocks Explained
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.